DelNova
Solving Botulinum Toxin Treatment Complications
Highland Park, IL
Biotechnology
Pharmaceutical
DelNova is solving unmet medical needs using known drugs in combination with drug delivery expertise and technologies.
We are currently looking to solve the undesirable side-effects from Botulinum toxin type-A [BoNT] injections, commonly used to reduce the appearance of facial wrinkles [e.g. BotoxⓇ] as well as for medical conditions such as migraine and other serious muscle disorders. ReViVox™, which is currently in development, is among the first solutions for [BoNT] complications. Our team has extensive experience in the science and pharma & biotech industries. CEO and Founder Mary Gardner has held leadership positions at Hospira, a Pfizer company and Lawson Health Research Institute.
$3,276
raised
5
Investors
$10M
Valuation Cap
6.0%
Annual Interest Rate
$500.00
Min. Investment
20.0%
Discount Rate
Conv. Note
Offering Type
03/28/24
Maturity Date
Reg CF
Offering
Rewards
Get rewarded for investing more into DelNova:
$500+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Reasons to Invest
Growing Market: Over $4.83 billion market for Botulinum Toxin in 2019, such as BOTOX®. Procedures have been approved in over 95 countries, and there were 7.7 million cosmetic procedures in 2019 in the U.S. alone.*
Rising Need: There is an estimated growth rate in Botulinum Toxin of 7.5 % per year, but the side effects of this neurotoxin are projected to hamper the global market growth* in future years.
Validation: Our product candidate is backed by pharma industry executives. DelNova has a unique patent protected position based on active pharmaceutical ingredients already approved for use globally for different medical conditions. As a virtual operation using best-in-class science and drug development institutions, we are able to maintain low overhead costs.
*Market statistics provided by Globe Newswire, Botox Cosmetic, and The American Society of Plastic Surgeons (source / source / source)
**Fortune Business Insights (source)
OVERVIEW
A new solution for BoNT complications
ReViVox™ is among the first solutions for the undesirable side effects of BoNT procedures, offering an opportunity to reduce patient anxieties, risks and improve quality of life. Botox, Dysport, Xeomin and Jeaveau are the US approved BoNT brands.
ReViVox is under development with proof-of-concept demonstrated in rodent models. It is not currently available on the market.
THE PROBLEM
Botulinum toxins - BoNT (e.g. Botox®) have distressing side effects
The WW market for botulinum neurotoxins (BoNT) such as BOTOX® is currently worth $5 billion, yet there is no remedy to resolve the concerning side effects. The most common symptom of reducing facial wrinkles through BoNT is droopy eyes or drooping brows (lid or brow ptosis). Other common complications from medical therapies of BoNT include muscle weakness and urinary retention in the treatment of over-active bladder.
The therapy is designed to rescue BTX toxin complications, will ease patient anxiety, and expand the growing market for neurotoxins in both cosmetic and medical uses.
THE SOLUTION
An injection designed to solve BoNT complications
ReViVox™ is a rescue therapy which can be administered to a targeted area of the body by injection to improve outcomes of the medical procedure.
ReViVox is under development with proof-of-concept demonstrated in rodent models. It is not currently available on the market.
The therapy is designed to rescue BoNT complications, will ease patient anxiety, and expand the growing market for neurotoxins in both cosmetic and medical uses.
THE MARKET
The global BTX market is worth $5 billion, and complications are on the rise
With $5 billion in sales, the global BTX market is booming. Cosmetic procedures account for over 40% of the BTX market. However, complications are on the rise often due to inexperienced injectors. According to an FDA study, there was a 5.4% incidence of ptosis (drooping eyelids) post market study in 2001. Since market penetration in facial aesthetics is only about 7%, it is not unrealistic to assume an additional $1 billion in BoNT revenues.
*ReViVox is under development with proof-of-concept demonstrated in rodent models. It is not currently available on the market.
We anticipate that the DelNova opportunity will be an attractive acquisition target for a strategic corporate investor. Market penetration in the medical aesthetic/cosmetic category is estimated at only 7%. DelNova offers an opportunity to grow the market by providing both physicians and patients a level of comfort or insurance against the possibility of bad outcomes. There have been several notable acquisitions in the pharmaceutical industry. In 2018, Allergan acquired Bonti Inc. which sold at the pre-market development stage for $195 million and Elastagen Pty. Ltd. for $260 million.
OUR TRACTION
US patent issued and preclinical success
Through testing we have demonstrated muscle restoration with ReViVox™. We have proven this in preclinical (animal) studies.
ReViVox is under development with proof-of-concept demonstrated in rodent models. It is not currently available on the market.
Since the active ingredient is already approved for other human medical conditions, we expect the drug to qualify for an expedited approval process known as 505b2 under FDA.
WHY INVEST
Multi-million dollar sales potential
There is the potential for $300+ MM in U.S. product sales of ReViVox™ and the expansion of the $5 billion annual WW base neurotoxin market through reduction of risk and patient anxiety.
ReViVox is under development with proof-of-concept demonstrated in rodent models. It is not currently available on the market.
The information included above is forward looking information. Please refer to our risk factors section in our Form C and to our Forward Looking Information Legend included in our Terms section on this page.
Quick Insert
Code View
Offering Summary
Company | : | DelNova, Inc. |
Corporate Address | : | 250 Poplar Road, Highland Park, IL 60035 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $500,000.00 |
Minimum Investment Amount(per investor) | : | $500.00 |
Terms
Offering Type | : | Convertible Promissory Notes |
Type of Equity Converted Into | : | Common Stock |
Conversion Trigger | : | $1,000,000.00 |
Maturity Date | : | March 28, 2024 |
Valuation Cap | : | $10,000,000.00 |
Discount Rate | : | 20.0% |
Annual Interest Rate | : | 6.0% |
What is a Convertible Note?
A convertible note offers you the right to receive Common Stock in DelNova, Inc. . The amount of Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $1,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $10,000,000.00 Valuation Cap or if less, then you will receive a 20.0% discount on the price the new investors are paying. You also receive 6.0% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).
*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.
The 10% StartEngine Owners' Bonus
DelNova, Inc. will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 6.6% instead of 6%.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Forward-Looking Information Disclaimer
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$511,090.00
USD
$499,257.00
USD
Cash And Cash Equivalents
$52,638.00
USD
$95,158.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$209.00
USD
$271.00
USD
Long Term Debt
$59,482.00
USD
$0.00
USD
Revenues And Sales
$5,252.00
USD
$22.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
-$47,587.00
USD
-$136,033.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
What is the Spread of Toxin Effect? LEARN MORE ... & how DelNova is working to alleviate its impact on daily lives.
4 days agoRead DelNova's WhitePaper on the RISK OF COMPLICATIONS ASSOCIATED WITH BOTULINUM TOXIN (BoNT) INJECTIONS. Follow this link on LifeSciencesReview.com and download the paper. WHITEPAPER
Why not be a part of the solution to this problem? and become an early investor.
For example, BoNTs are approved to treat a condition called hyperhidrosis, also referred to as sweaty palms. "Muscle weakness of finger grip has been reported as a reversible side-effect of this new treatment" . Swartling, C., Färnstrand, C., Abt, G., Stålberg, E., & Naver, H. (2001). Side-effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. European journal of neurology, 8(5), 451–456. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1468-1331.2001.00261.x
Still in Denial?..... BoNT complications are Real, DelNova can help. Don't miss your chance to Invest!
19 days agoRecent Headlines in MedAesthetics newsletter>
Study Reveals Botulinum Toxin Complication Rates at 16%
Apr 27th, 2022
16 percent of patients experience a complication following botulinum toxin injections in the glabellar and forehead regions.A review of complication rates following botulinum toxin A (BoNT-A) injections in the glabellar region and forehead found that 16% of patients experience adverse events, including headache, local skin reactions and facial neuromuscular symptoms.
Go to www.delnova.net for information on how we can help solve this issue.
Mary Gardner, CEO & Founder
P.Eng., MBA, CLP
Notice of Material Change in Offering
26 days ago[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the DelNova offering. Here's an excerpt describing the specifics of the change:
Material Change-Extension
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
Message from the CEO - Help us with our FIX for BoNT Side-Effects
27 days agoShare our DelNova News Release!
DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxin neuromodulators, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®. DelNova's US patent has been granted. To fund its continuing development program, DelNova has launched an equity crowdfunding campaign with StartEngine https://www.startengine.com/delnova. DelNova is excited to announce that Dr. Steven Yoelin (Orange County, CA), a leading medical practitioner and injector of neuromodulators, has joined the team as Chief Medical Strategist.
Why Miss this Opportunity? Spread the word - Invest before it's too late.
30 days agoDelNova has been picked up in Industry News -- MedEsthetics Magazine
Medesthetics has news, features and education about noninvasive cosmetic therapies, trends, products and equipment for medical professionals and spa owners and managers in the US.
Meet Dr. Steve Yoelin MD - Chief Medical Strategist to DelNova
about 1 month ago
Dr. Steve Yoelin, MD, operates a private practice that focuses on injectable medical aesthetics procedures and has a multiyear waitlist, which he has built exclusively from repeat visits and word-of-mouth referrals. He has trained other clinicians through 2,000+ industry-sponsored global training programs and hundreds of continuing medical education (CME) programs. He has also led dozens of clinical trials (Phases 1 - 4) and has authored or coauthored many peer-reviewed journal articles, posters, and presentations. He has been awarded several patents for his research. He completed his ophthalmology residency at and received his Doctor of Medicine degree from the University of California, Irvine. He received his Bachelor of Science degree from the University of California, Davis.
Time is running out.....
about 1 month ago...to get in on the ground floor of an innovation that is the first PROMISING Solution to botulinum toxin (e.g. BOTOX®) complications.
Read about Ptosis (Droopy Eye) by Dr. Ana Mansouri https://www.glowday.com/blog/what-is-ptosis
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}